MyHep All, also known as “EPCLUSA®, Velpanat, Sofosvel, Hepcvel, Velasof” is a fixed dose combination medication for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis. MyHep All combines Sofosbuvir 100mg and velpatasvir 400mg. It is more than 90% effective for hepatitis C. Sofosbuvir 100mg/Velpatasvir 400 mg’s brand name is EPCLUSA® by Gilead.
DOSAGE AND ADMINISTRATION
1. Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc.
2. Recommended dosage: One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food
3. See recommended treatment regimen and duration in patients with genotypes 1, 2, 3, 4, 5, or 6 HCV in table below:
MyHep All is a generic oncologic prescription medicine from Mylan, which is one of the biggest pharmaceutical company in India.
For more Prescribing information，please check the → “FDA Prescribing Information”.